Nightingale Health Plc, a pioneer in blood analysis technology for detecting disease risks, is reshaping its management team to drive the next phase of its healthcare business growth. This follows the global adoption of Nightingale Health’s technology and the advancement of healthcare implementation projects. The renewed leadership structure will focus on scaling the clinical use of Nightingale Health’s technology worldwide and accelerating commercial growth. The company will continue product development efforts but the main focus will shift to the growth phase of healthcare business.

The following changes will take place in the management team as part of the restructuring:

• Jeffrey Barrett, CSO since September 2021, will leave the company by March 2026 at the latest.
• Instead of appointing a new CSO, Nightingale Health will recruit a Chief Medical Officer (CMO) to strengthen expertise in clinical work and the commercial adoption of innovative medical solutions.
• Management team members Dr. Salla Ruosaari, Chief R&D Officer, and Antti Kangas, Chief Technology Officer and one of the company’s founders, will oversee scientific operations until further notice.
• Following the announcement on December 8, 2025, Nightingale has begun recruiting a new CFO. The role will focus on designing and implementing structures to support international commercial growth and sales expansion.

With these changes, Nightingale Health Plc’s management team will be well positioned to significantly increase its efforts to healthcare business growth.

“We are entering the next stage in implementing our vision, and to support this, we are reshaping our management team. This will enable us to achieve our ambitious goal of building better healthcare for everyone. I want to thank Jeffrey for his contributions over the years and wish him success in the future,” said Teemu Suna, CEO and Founder of Nightingale Health.